American Oriental Bioengineering Announces Boke Subsidiary Passes Inspection
NEWARK, N.J., June 9, 2012 /PRNewswire-Asia-FirstCall/ — American Oriental Bioengineering, Inc., (the “Company” or “AOBI”), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter (“OTC”) products, today announced that Boke Pharmaceutical Co, Ltd., one of the Company’s wholly owned subsidiaries has passed the short notice inspections of its capsule products directed by China State Food and Drug Administration (“SFDA”).
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company’s filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
Contact: American Oriental Bioengineering, Inc. Kewa Luo (646) 367-1765
SOURCE American Oriental Bioengineering, Inc.